| abstract |
The present disclosure relates to new compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula I n n n n n n n n n n as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of cancer in mammals (e.g. humans). |